Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo, Oslo, Norway.
Department of Pediatrics, Oslo University Hospital, Oslo, Norway.
Support Care Cancer. 2022 Dec;30(12):10233-10241. doi: 10.1007/s00520-022-07405-8. Epub 2022 Oct 29.
To investigate oral and dental late effects in survivors of childhood brain tumors medulloblastoma (MB) and central nervous system supratentorial primitive neuroectodermal tumor (CNS-PNET).
This cross-sectional study assessed oral and dental late effects in MB/CNS-PNET survivors treated before 20 years of age, and with a minimum of 2 years since treatment. Participants went through an oral and radiographic examination. We assessed oral status using the decayed-missing-filled index (DMFT), oral dryness, maximum mouth opening (MMO), fungal infection, and registration of dental developmental disturbances (DDD) in the form of hypodontia, microdontia, and enamel hypoplasia.
The 46 participants' mean age at enrolment was 27 ± 12.8 years and at treatment 8.5 ± 5.2 years, and the mean time since treatment was 18.9 ± 12 years. Over a third (35%) of survivors had reduced mouth opening (mean 29.3 ± 5.6 mm (range 16-35)). A significantly lower MMO was found in individuals treated ≤ 5 years compared to survivors treated > 5 years (p = 0.021). One or more DDD were registered in 30.4% of the survivors, with a significantly higher prevalence in individuals treated ≤ 5 years (p < 0.001). Hypodontia was the most prevalent type of DDD. There was no difference in DMFT score in relation to age at treatment. Oral dryness was not frequently reported or observed in these survivors.
Survivors of childhood MB/CNS-PNET are at risk of oral and dental late effects including reduced mouth opening and DDD. The risk is highest in survivors treated before the age of 5.
研究儿童脑肿瘤髓母细胞瘤（MB）和中枢神经系统幕上原始神经外胚层肿瘤（CNS-PNET）幸存者的口腔和牙齿晚期效应。
本横断面研究评估了 20 岁前接受治疗且治疗后至少 2 年的 MB/CNS-PNET 幸存者的口腔和牙齿晚期效应。参与者接受了口腔和放射学检查。我们使用龋失补牙指数（DMFT）、口腔干燥、最大张口度（MMO）、真菌感染以及缺牙、牙小畸形和釉质发育不全等形式的牙发育障碍（DDD）登记来评估口腔状况。
46 名参与者的入组平均年龄为 27±12.8 岁，治疗时为 8.5±5.2 岁，治疗后平均时间为 18.9±12 年。超过三分之一（35%）的幸存者张口受限（平均 29.3±5.6mm（范围 16-35））。与治疗后 5 年以上的幸存者相比，治疗后 5 年以下的幸存者 MMO 明显较低（p=0.021）。30.4%的幸存者有 1 种或多种 DDD，治疗后 5 年以下的幸存者 DDD 发生率明显较高（p<0.001）。牙缺失是最常见的 DDD 类型。与治疗年龄无关，DMFT 评分无差异。这些幸存者中口腔干燥症并不常见。
儿童 MB/CNS-PNET 幸存者存在口腔和牙齿晚期效应的风险，包括张口受限和 DDD。5 岁前治疗的幸存者风险最高。
